Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Molecular Biology Laboratory, |
RCV001281242 | SCV001425066 | likely pathogenic | Nephrotic syndrome, type 9 | 2020-02-01 | criteria provided, single submitter | research | |
Precision Medicine Center, |
RCV001281242 | SCV001593083 | uncertain significance | Nephrotic syndrome, type 9 | criteria provided, single submitter | research | PM1,PM2,PP3 | |
Gene |
RCV001575910 | SCV001803001 | uncertain significance | not provided | 2020-11-18 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 32543055, 28204945, 28405841, 30470792, 29382012, 32957916) |
3billion | RCV001281242 | SCV002572856 | pathogenic | Nephrotic syndrome, type 9 | 2022-09-01 | criteria provided, single submitter | clinical testing | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.006%). Same nucleotide change resulting in same amino acid change has been previously reported to be associated with COQ8B-related disorder (PMID: 28204945). The variant has been reported to be in trans with a pathogenic variant as either compound heterozygous or homozygous in at least 4 similarly affected unrelated individuals (PMID: 28204945 , 28405841 , 30076350 , 33413146 , 33532864 , 34172776). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline. |
Juno Genomics, |
RCV001281242 | SCV005417198 | likely pathogenic | Nephrotic syndrome, type 9 | criteria provided, single submitter | clinical testing | PM2_Supporting+PM3_Strong+PP4 |